Does Zepbound make birth control pills less effective?

The tirzepatide label warns it may reduce oral-contraceptive effectiveness and advises a non-oral or added barrier method for 4 weeks after starting and after each dose increase. Discuss options with your clinician.

How much weight did people lose on tirzepatide?

In SURMOUNT-1, adults on the highest tirzepatide dose lost up to about 20.9% of body weight over 72 weeks. The trial reported overall results and did not establish an FDA-approved difference by sex.

Is Zepbound approved for PCOS?

No. Zepbound is approved for chronic weight management, not PCOS. The 2023 International PCOS Guideline lists anti-obesity medications as an adjunct where weight loss is a goal, so PCOS use is off-label.

GIP/GLP-1 receptor dual agonist (tirzepatide)

Zepbound (Tirzepatide) for Women: What to Know

Medically reviewed by Editorial Medical Review, MD, NAMS-CMP · Updated July 2026

Quick answer

Zepbound is the brand name for tirzepatide, a once-weekly injection that activates both GIP and GLP-1 receptors and is FDA-approved for chronic weight management. For women, its label uniquely warns that it may reduce the effectiveness of oral birth control, and the label advises stopping it before a planned pregnancy.

How it works

Tirzepatide activates two gut-hormone receptors, GIP and GLP-1, reducing appetite and slowing gastric emptying. In the SURMOUNT-1 trial, adults on the highest dose lost up to about 20.9% of body weight over 72 weeks, versus about 3.1% on placebo.

FDA status for weight: FDA-approved for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition.

Women-specific considerations

These are factual notes from FDA labels and published guidelines, not personal medical advice. Discuss your situation with a licensed clinician.

Oral birth control

The tirzepatide FDA label warns it may reduce the effectiveness of oral hormonal contraceptives. The label advises switching to a non-oral method or adding a barrier method for 4 weeks after starting and for 4 weeks after each dose increase.

Pregnancy

The label advises discontinuing tirzepatide before a planned pregnancy; it is not recommended during pregnancy. This is a label instruction, not personal advice.

Breastfeeding

There is no human data on tirzepatide in breast milk, and the label does not recommend use while breastfeeding.

PCOS

Tirzepatide is not FDA-approved for PCOS. The 2023 International PCOS Guideline recognizes anti-obesity medications as an adjunct where weight management is a goal, so any PCOS use is off-label.

Perimenopause weight

Zepbound is approved by BMI, not by menopausal status. No menopause-specific trials establish a different effect for midlife women.

Who it is for (eligibility)

The FDA label indicates Zepbound for adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) plus a weight-related condition. A licensed clinician determines suitability.

Cost (cited)

LillyDirect self-pay vial (2.5 mg)

$349/mo

LillyDirect Self Pay program (Zepbound vials $349-$599/mo) ↗

LillyDirect self-pay vial (5-10 mg)

$499/mo

LillyDirect Self Pay program (Zepbound vials $349-$599/mo) ↗

Commercial insurance + savings card

$25/mo

Zepbound coverage and savings ↗

Retail list price

$1,086/mo

GoodRx — Zepbound price guide (list + discounted) ↗

See the full cost breakdown in our cost guide.

Providers we review that offer this

Editorial reviews only — not treatment recommendations. Prescribing decisions rest with a licensed clinician. For the full directory, see all GLP-1 for women providers.

Form Health — Board-certified obesity medicine physicians prescribing GLP-1s. Often insurance-covered — among the most affordable options when insurance applies.
Mochi Health — Doctor-led GLP-1 weight loss program. Offers compounded semaglutide/tirzepatide and FDA-approved Wegovy/Zepbound for eligible patients.
Calibrate (Insurance) — Calibrate’s insurance-billing arm for women whose employer plan covers Wegovy or Zepbound.
Plushcare GLP-1 — Primary care telehealth that prescribes Wegovy and Zepbound when clinically appropriate. Insurance-friendly.

Frequently asked questions

Does Zepbound make birth control pills less effective?: The tirzepatide label warns it may reduce oral-contraceptive effectiveness and advises a non-oral or added barrier method for 4 weeks after starting and after each dose increase. Discuss options with your clinician.
How much weight did people lose on tirzepatide?: In SURMOUNT-1, adults on the highest tirzepatide dose lost up to about 20.9% of body weight over 72 weeks. The trial reported overall results and did not establish an FDA-approved difference by sex.
Is Zepbound approved for PCOS?: No. Zepbound is approved for chronic weight management, not PCOS. The 2023 International PCOS Guideline lists anti-obesity medications as an adjunct where weight loss is a goal, so PCOS use is off-label.

Sources

Every claim above resolves to an FDA label, published trial, guideline, or manufacturer / GoodRx pricing page. External links open in a new tab.

For the general (non women-specific) mechanism, dosing, and side-effect incidence, see our tirzepatide medication overview.

Compare other options

Wegovy for women — GLP-1 receptor agonist (semaglutide 2.4 mg)
Compounded tirzepatide for women — Compounded GIP/GLP-1 dual agonist (tirzepatide)
Ozempic for women — GLP-1 receptor agonist (semaglutide)
Back to the GLP-1 for women guide

ClearHormones updates this explainer as FDA status and pricing change. Verify current approval status and pricing on the manufacturer or FDA page before acting.